From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics

[1]  S. Kaul,et al.  ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association , 2010, Circulation.

[2]  B. Yan,et al.  Role of warfarin pharmacogenetic testing in clinical practice. , 2010, Pharmacogenomics.

[3]  Janet Woodcock,et al.  Pharmacogenetics--tailoring treatment for the outliers. , 2009, The New England journal of medicine.

[4]  Charles E. Leonard,et al.  CYP2C9, CYP2C19, and ABCB1 Genotype and Hospitalization for Phenytoin Toxicity , 2009, Journal of clinical pharmacology.

[5]  R. Dworkin,et al.  Treatment of neuropathic pain: an overview of recent guidelines. , 2009, The American journal of medicine.

[6]  I. Cascorbi,et al.  Conference Scene: Pharmacogenomics at the second PharmSciFair 2009: adverse drug reactions and clinical implementation. , 2009, Pharmacogenomics.

[7]  M. Daly,et al.  HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin , 2009, Nature Genetics.

[8]  L. Becquemont,et al.  Pharmacogenomics of adverse drug reactions: practical applications and perspectives. , 2009, Pharmacogenomics.

[9]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[10]  E. Antman,et al.  Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial , 2009, The Lancet.

[11]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[12]  Erika Check Hayden,et al.  Genome sequencing: the third generation , 2009, Nature.

[13]  B. Franke,et al.  HTR2C Gene Polymorphisms and the Metabolic Syndrome in Patients With Schizophrenia: A Replication Study , 2009, Journal of clinical psychopharmacology.

[14]  S‐M Huang,et al.  Is This the Drug or Dose for You?: Impact and Consideration of Ethnic Factors in Global Drug Development, Regulatory Review, and Clinical Practice , 2008, Clinical pharmacology and therapeutics.

[15]  M. Ingelman-Sundberg,et al.  Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects , 2008, European Journal of Clinical Pharmacology.

[16]  K. Hillgren,et al.  PhRMA White Paper on ADME Pharmacogenomics , 2008, Journal of clinical pharmacology.

[17]  P. Weihe,et al.  CYP2D6 Polymorphism in Relation to Tramadol Metabolism: A Study of Faroese Patients , 2008, Therapeutic drug monitoring.

[18]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte , 2008, Clinical pharmacology and therapeutics.

[19]  G. Jenkins,et al.  Pharmacokinetic Genes Do Not Influence Response or Tolerance to Citalopram in the STAR*D Sample , 2008, PloS one.

[20]  K. P. Mathews,et al.  Acenocoumarol and phenytoin toxicity in the presence of CYP2C9 mutation. , 2008, The Journal of the Association of Physicians of India.

[21]  S. Mallal,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.

[22]  H. Refsum,et al.  Impact of the Ultrarapid CYP2C19*17 Allele on Serum Concentration of Escitalopram in Psychiatric Patients , 2008, Clinical pharmacology and therapeutics.

[23]  Jung-Eun Choi,et al.  Lack of association between the −759C/T polymorphism of the 5‐HT2C receptor gene and olanzapine‐induced weight gain among Korean schizophrenic patients , 2008, Journal of clinical pharmacy and therapeutics.

[24]  J. Brockmöller,et al.  Effects of the CYP2D6 Gene Duplication on the Pharmacokinetics and Pharmacodynamics of Tramadol , 2008, Journal of clinical psychopharmacology.

[25]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[26]  S. Narayan,et al.  Severe phenytoin toxicity in a CYP2C9*3*3 homozygous mutant from India. , 2007, Neurology India.

[27]  J. Kennedy,et al.  Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. , 2007, The international journal of neuropsychopharmacology.

[28]  B. Franke,et al.  The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study , 2007, The Pharmacogenomics Journal.

[29]  Henk-Jan Guchelaar,et al.  Translating Pharmacogenomics: Challenges on the Road to the Clinic , 2007, PLoS medicine.

[30]  B. Franke,et al.  The Association Between HTR2C Gene Polymorphisms and the Metabolic Syndrome in Patients With Schizophrenia , 2007, Journal of clinical psychopharmacology.

[31]  Soo-Youn Lee,et al.  Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting. , 2007, Journal of biochemistry and molecular biology.

[32]  Y. Wing,et al.  Phenotype-genotype Relationship and Clinical Effects of Citalopram in Chinese Patients , 2006, Journal of clinical psychopharmacology.

[33]  G. Reynolds,et al.  The 5-HT2C receptor and antipsychoticinduced weight gain – mechanisms and genetics , 2006, Journal of psychopharmacology.

[34]  C. Adithan,et al.  Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India. , 2006, The Indian journal of medical research.

[35]  H. Refsum,et al.  Heterozygous Mutation in CYP2C19 Significantly Increases the Concentration/Dose Ratio of Racemic Citalopram and Escitalopram (S-citalopram) , 2006, Therapeutic drug monitoring.

[36]  L. Arendt-Nielsen,et al.  The Analgesic Effect of Tramadol After Intravenous Injection in Healthy Volunteers in Relation to CYP2D6 , 2006, Anesthesia and analgesia.

[37]  G. Reynolds,et al.  The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[38]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[39]  Josemir W Sander,et al.  Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  G. Reynolds,et al.  Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis , 2005, Pharmacogenetics and genomics.

[41]  M. Margaglione,et al.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005 .

[42]  Chih-Chuan Chen,et al.  Dosage Recommendation of Phenytoin for Patients with Epilepsy with Different CYP2C9/CYP2C19 Polymorphisms , 2004, Therapeutic drug monitoring.

[43]  Urs A. Meyer,et al.  Pharmacogenetics – five decades of therapeutic lessons from genetic diversity , 2004, Nature Reviews Genetics.

[44]  J. Hebebrand,et al.  Lack of association between the –759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals , 2004, Psychiatric genetics.

[45]  Yuan-Tsong Chen,et al.  A marker for Stevens–Johnson syndrome , 2004 .

[46]  Andreas Fregin,et al.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 , 2004, Nature.

[47]  A. Khvorova,et al.  Identification of the gene for vitamin K epoxide reductase , 2004, Nature.

[48]  S. Takashiba,et al.  CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. , 2004, Life sciences.

[49]  T. Thum,et al.  A rapid and simple CYP2D6 genotyping assay--case study with the analgetic tramadol. , 2003, Metabolism: clinical and experimental.

[50]  Zhaoqian Liu,et al.  Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[51]  L. Bertilsson,et al.  Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. , 2003, British journal of clinical pharmacology.

[52]  A. Hoeft,et al.  Impact of CYP2D6 genotype on postoperative tramadol analgesia , 2003, Pain.

[53]  G. Reynolds,et al.  Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. , 2003, The American journal of psychiatry.

[54]  R. Weinshilboum.  Inheritance and drug response. , 2003, The New England journal of medicine.

[55]  R. Ismail,et al.  Correlation of tramadol pharmacokinetics and CYP2D6*10 genotype in Malaysian subjects. , 2002, Journal of pharmaceutical and biomedical analysis.

[56]  G. Kearns,et al.  Concordance between Tramadol and Dextromethorphan Parent/Metabolite Ratios: The Influence of CYP2D6 and Non‐CYP2D6 Pathways on Biotransformation , 2002, Journal of clinical pharmacology.

[57]  A. Wood,et al.  Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo. , 2001, Pharmacogenetics.

[58]  E. Spina,et al.  Severe phenytoin intoxication in a subject homozygous for CYP2C9*3 , 2001, Clinical pharmacology and therapeutics.

[59]  J. Weide,et al.  The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. , 2001, Pharmacogenetics.

[60]  N. Peet,et al.  Pharmacogenomics: challenges and opportunities. , 2001, Drug discovery today.

[61]  D. Collier,et al.  Pharmacogenetic prediction of clozapine response , 2000, The Lancet.

[62]  S. Higuchi,et al.  Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. , 2000, Therapeutic drug monitoring.

[63]  J. Brockmöller,et al.  Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. , 1999, British journal of clinical pharmacology.

[64]  M C Meyer,et al.  Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. , 1999, Pharmacogenetics.

[65]  J. Lieberman,et al.  Serotonergic basis of antipsychotic drug effects in schizophrenia , 1998, Biological Psychiatry.

[66]  E. Yukawa,et al.  The Effects of Genetic Polymorphisms of CYP2C9 and CYP2C 19 on Phenytoin Metabolism in Japanese Adult Patients with Epilepsy: Studies in Stereoselective Hydroxylation and Population Pharmacokinetics , 1998, Epilepsia.

[67]  R. Frye,et al.  Debilitating Reaction following the Initial Dose of Tramadol , 1997, The Annals of pharmacotherapy.

[68]  K. Furusho,et al.  Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy , 1997, Clinical pharmacology and therapeutics.

[69]  L. Arendt-Nielsen,et al.  The hypoalgesic effect of tramadol in relation to CYP2D6 * , 1996, Clinical pharmacology and therapeutics.

[70]  B. Wilffert,et al.  Influence of tramadol on neurotransmitter systems of the rat brain. , 1996, Arzneimittel-Forschung.

[71]  M. Takano,et al.  Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. , 1996, Biological & pharmaceutical bulletin.

[72]  P. Baumann,et al.  A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. , 1996, Journal of clinical psychopharmacology.

[73]  K. Brøsen,et al.  Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation Polymorphisms , 1993, Therapeutic drug monitoring.

[74]  M. Bullock,et al.  Phenytoin Toxicity Due to Genetic Polymorphism , 2009, Neurocritical care.

[75]  M. Niermeijer.  [Partial resistance to acenocoumarol and phenprocoumon caused by enzyme polymorphism]. , 2006, Nederlandsch tijdschrift voor geneeskunde.

[76]  U. Brinkmann,et al.  The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels , 2001, The Pharmacogenomics Journal.

[77]  H. Dengler,et al.  PHARMACOKINETICS AND DISPOSITION , 1997 .